MAP2K1 and acute myeloid leukemia: If this is the case, it would be interesting to determine whether AML cells with high basal levels of STAT3 activation, and presumably addicted to this transcription factor, might be particularly susceptible to the MEK1/2/Src inhibitory strategy.